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ABSTRACT
The association of Epstein-Barr virus (EBV) with oral cancer has been widely reported in the past. However, previous studies 
mainly focused on the current infection of EBV without acknowledging the possibility of past infection in patients which 
may lead to oral cancer development. The present study aims to investigate the correlation between past EBV infections 
with Oral Squamous Cell Carcinoma (OSCC). Both Immunoglobulin M (IgM) and Immunoglobulin G (IgG) antibodies 
against EBV were screened to detect the presence of EBV in sera of OSCC patients using Enzyme-Linked Immunosorbent 
Assay (ELISA). The use of IgM antibody against EBV confirms current infection in patients, whereas IgG antibody would 
predict past infection throughout patients’ lifetime. Through the present study, we would be able to confirm whether 
patients with past EBV infection have a significant risk in developing oral cancer. ELISA tests were carried out to detect 
the presence of EBV IgG and IgM in 206 OSCC and control serum samples. Statistical analysis was performed using SPSS 
12.0.1. Our results had shown that 96.6% (n = 199) of OSCC samples and 97.2% (n = 130) control were positive with 
EBV VCA IgG, however, none of the OSCC and control samples was positive for EBV VCA IgM. The presence of EBV VCA 
IgG in both OSCC and control suggest that past EBV infection does not play a significant role as a risk indicator for OSCC. 
Therefore, the association between EBV and OSCC was not well demonstrated in this study.
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ABSTRAK
Hubung kait virus Epstein-Barr (EBV) dengan kanser mulut telah banyak dilaporkan sebelum ini. Namun demikian, 
kajian terdahulu lebih tertumpu kepada jangkitan semasa EBV tanpa mengambil kira kebarangkalian jangkitan masa 
lalu pada pesakit yang boleh menyebabkan perkembangan kanser mulut. Tujuan kajian ini dijalankan adalah untuk 
mengkaji korelasi antara jangkitan EBV yang lalu dengan Karsinoma Sel  Skuama Mulut (OSCC). Kedua-dua antibodi 
Imunoglobulin M (IgM) dan Imunoglobulin M (IgG) terhadap EBV telah dikesan menggunakan Asai Imunojerapan 
Berpaut Enzim (ELISA) untuk mengenal pasti kehadiran EBV dalam sera pesakit OSCC. Antibodi IgM terhadap 
EBV digunakan untuk mengesahkan jangkitan semasa pada pesakit, manakala antibodi IgG dapat menjangkakan 
kebarangkalian jangkitan masa lalu sepanjang hayat pesakit. Melalui kajian ini, kami boleh mengesahkan sama ada 
pesakit yang mengalami jangkitan EBV yang lalu mempunyai tahap risiko tinggi dalam permulaan OSCC. Ujian ELISA 
dijalankan untuk mengesan kehadiran EBV IgG dan IgM dalam 206 sampel serum OSCC dan kawalan. Analisis statistik 
dijalankan menggunakan SPSS 12.0.1. Berdasarkan hasil kajian ini, didapati 96.6% (n = 199) sampel OSCC dan 97.2% 
(n = 130) sampel kawalan, positif dengan EBV VCA IgG. Akan tetapi, tiada sampel OSCC dan kawalan positif terhadap 
EBV VCA IgM. Kehadiran IgG VCA EBV dalam kedua-dua sampel OSCC dan kawalan mencadangkan bahawa jangkitan 
EBV yang lalu tidak memainkan peranan penting sebagai penanda risiko terhadap OSCC. Oleh yang demikian, hubung 
kait antara EBV dan OSCC tidak dapat dibentangkan dengan baik dalam kajian ini.
Kata kunci: Asai imunojerapan berpaut enzim; imunoglobulin G (IgG); imunoglobulin M (IgM); karsinoma sel skuama 
mulut; virus Epstein-Barr
INTRODUCTION
Oral cancer is classified under the Head and Neck 
cancer. It was reported as the sixth most prevalent cancer 
worldwide (Tang et al. 2015). Oral cancer has been ranked 
as the 17th most common cancer worldwide and 16th 
most common cancer with a high mortality rate (Ferlay 
et al. 2018). Consequently, the mortality rate of oral 
cancer remains high, which is at approximately 50% of 
the overall mortality rate (Le Campion et al. 2017). Oral 
squamous cell carcinoma (OSCC) which originates from 
1970 
the mucosal lining represents 90% of oral cancer and 
remains as a major health problem in many parts of the 
world (Sand & Jalouli 2014; Syrjänen et al. 2011). The 
development of OSCC has been widely associated with 
several known risk factors such as tobacco and betel quid 
chewing, alcohol consumption and smoking (Acharya et 
al. 2015; Rosnah et al. 1999). However, there are several 
other risk factors that have been identified in association 
with the development of OSCC such as ionising radiation, 
genetic predisposition, Human Papilloma Virus (HPV) and 
Epstein Barr Virus (EBV) infection (Kumar et al. 2016; 
Scully & Bagan 2009). 
 One of the prominent viruses associated with oral 
cancer is EBV. EBV is a member of the herpes virus family 
which infects approximately 90% of the world’s adult 
population (Danielsson et al. 2018; Sand et al. 2002). 
EBV is also well known to be associated with infectious 
mononucleosis, Burkitt’s lymphoma, B-cell lymphoma, 
Hodgkin’s disease, peripheral T-cell lymphoma, 
nasopharyngeal carcinoma, oral hairy leukoplakia, gastric 
carcinoma and OSCC (Macsween & Johannessen 2014; 
Patel 2014; Prabhu & Wilson 2016; Yen et al. 2009). EBV 
primary infection occurs within the early years of life with 
no symptoms, and the virus persists throughout the life 
in the B-lymphocytes and leads to the shedding of the 
virus particles from the oral epithelium when re-activated 
(Jayasooriya et al. 2015; Purushothaman & Verma 2014; 
Shimakage et al. 2002). In primary infection, EBV infects 
and replicates in the oropharynx epithelial cells and 
expresses proteins causing cell proliferation (Cohen 2015; 
Thompson & Kurzrock 2004). In this phase, antibodies 
IgG, IgM and IgA are produced in response to EBV Viral 
Capsid Antigen (VCA) (Hanlon et al. 2014; Thompson 
& Kurzrock 2004). EBV infected individuals carry EBV 
throughout their whole life without presenting any illness 
and these individual usually show an elevated EBV VCA-
IgG (Abbott et al. 2017; Riordan et al. 1996). 
 EBV has been strongly associated with nasopharyngeal 
carcinoma. In recent years, EBV was found in numerous 
tumours such as breast (Arbach et al. 2006; Mezher et 
al. 2017), cervix (de Lima et al. 2018), gastric (Rugge et 
al. 2015), or gastrointestinal tract (Mirzaei et al. 2018), 
kidney (Bamoulid et al. 2017; Creager et al. 1998), 
lung (Wang et al. 2016), skin (Litvinov et al. 2016), 
and thyroid (Stamatiou et al. 2016). However, the exact 
role of the virus in the development of cancer remains 
uncertain. Although several reports have suggested the 
association of EBV with OSCC, the exact contribution of 
EBV to the development of oral carcinogenesis is still 
unclear (Kumar et al. 2016; Sand & Jalouli 2014). 
 The present study aims to investigate the correlation 
between past EBV infections with OSCC. Indirect Enzyme-
Linked Immunosorbent Assay (ELISA) was applied to 
detect the presence of IgG and IgM antibodies against 
EBV VCA in OSCC sera.
MATERIALS AND METHODS
SAMPLE COLLECTION
A total of 206 OSCC sera and 134 sera from non-OSCC 
individuals (control group) were obtained from the 
Malaysian Oral Cancer Database & Tissue Bank System 
(MOCDTBS) (Rosnah et al. 2013) coordinated by the Oral 
Cancer Research & Coordinating Centre (OCRCC), Faculty 
of Dentistry, University of Malaya. Approval for this 
study was obtained from the Medical Ethics Committee 
of Faculty of Dentistry, University of Malaya (ref no: DF 
DR1307/0077(U)). 
DETECTION OF ANTIBODIES AGAINST EBV VCA
VCA of EBV IgG and IgM antibodies in patient sera were 
detected using EBV VCA IgG and IgM ELISA kits based 
on the manufacturer’s protocols (Diagnostic Automation 
Inc, CA, USA). These ELISA micro-well strips were pre-
sensitized with EBV antigen by passive absorption. All sera 
samples were diluted to obtain a uniform concentration 
using the provided sample diluents. The sample diluents 
for EBV VCA IgM ELISA contains antihuman IgG. This 
anti-human IgG precipitated and removed IgG and 
rheumatoid factor leaving only IgM in the samples to 
react with the immobilized antigen. The diluted sera 
samples were then added to the strips and incubated for 
25 min at 25°C. After thorough washing, Peroxidase 
Conjugates goat anti-human IgG (γ chain specific)/
IgM (μ chain specific) was added in and the strips were 
further incubated for 25 min at 25°C. The wells were 
subsequently washed and 3,3’,5,5’-Tetramethylbenzidine 
(TMB) substrate solution was pipetted into each well and 
incubated for 15 min at 25°C. The peroxidase substrate 
solution was added to terminate the enzyme-substrate 
reaction. These changes were then measured using 450 
nm using a microplate reader (Tecan Infinite m200 Pro, 
Tecan Group Ltd., Mannedorf) spectrophotometrically. 
EBV antibody’s (IgG or IgM) valence in the samples was 
detected through optical density (OD) according to the 
manufacturer’s protocol and was further correlated to 
the Calibrator. The cut-off level for seropositivity was 
determined according to the manufacturer’s guidelines. 
The positive and negative controls were provided with 
the kit.
STATISTICAL ANALYSIS
All statistical analyses in this study were conducted 
using the Statistical Package for the Social Sciences 
(SPSS) software version 12.0.1. In addition, to determine 
whether variables such as EBV IgG/IgM, gender, race and 
age were predictors of OSCC, logistic regression analysis 
was conducted. The assumption on independent errors, 
normality, multicollinearity, nomoscedasticity, and outliers 
were examined (Kerishnan et al. 2016).
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RESULTS AND DISCUSSION
EBV belongs to the herpes virus family which infects 
approximately 90% of the world’s adult population 
(Danielsson et al. 2018; Sand et al. 2002). EBV infection 
is associated with various cancers such as infectious 
mononucleosis, Burkitt’s lymphoma, nasopharyngeal 
carcinoma, oral hairy leukoplakia and OSCC (Macsween 
& Johannessen 2014; Patel 2014).
 EBV infection was reported to be correspondent to 
the increased risk of OSCC (She et al. 2017). Studies have 
shown that EBV infected individuals usually carry the 
virus throughout their whole life without any symptoms 
and present elevated EBV VCA-IgG (Hanlon et al. 2014; 
Jenson 2011). Therefore, it had been suggested that the 
past or the long-term exposure to viruses may contribute 
to the onset of OSCC (Gupta & Metgud 2013). Similarly, in 
our previous association study on Human Papillomavirus 
(HPV) 16 in OSCC, HPV16 IgG antibodies were identified 
as a significant indicator of OSCC risk factor and further 
supporting that past exposure to HPV could increase the 
risk of OSCC (Kerishnan et al. 2016). 
 To identify the presence of EBV in patients, many 
of the previous studies applied methods such as in situ 
hybridization and polymerase chain reaction (PCR) to 
detect viral deoxyribonucleic acid (DNA) and ribonucleic 
acid (RNA) transcripts (Syrjänen et al. 2011; Yen et al. 
2009). However, these methods are expensive, time-
consuming and unable to determine past exposure of 
EBV (Petter et al. 2000; Salehi et al. 2016). Therefore, 
in the present study, the presence of both IgG and IgM 
antibodies against EBV were determined using ELISA. 
Through IgG and IgM screening, the patients’ past and 
current exposure status against EBV were confirmed. The 
presence of IgM antibodies against the virus directly 
shows acute or current exposure, whereas, IgG antibodies 
against virus indicate past exposure to the virus. 
DEMOGRAPHIC PROFILE
A total of 206 OSCC patients (cases) and 134 non-OSCC 
patients (control) representing a mean age of 58.8±14.2 and 
33.5±8.6, respectively, were included in this investigation. 
Based on the socio-demographic profiles of OSCC patient 
recruited in this study, female (67.0%) Indians (49.5%) 
were found to be the highest number of patients diagnosed 
with OSCC (Table 1). 
 Although the high incidence of oral cancer is generally 
associated with tobacco smoking, betel quid chewing and 
alcohol consumption, viruses are also known to play a role 
in OSCC development (Kumar et al. 2016; Polz-Gruszka et 
al. 2014). The general causative virus for OSCC includes 
EBV (Jalouli et al. 2010; Sand & Jalouli 2014).
EBV VCA SEROLOGICAL ANALYSIS
To evaluate the seropositivity of EBV VCA in OSCC (n=206) 
and control (n=134) patients, EBV VCA ELISA assays were 
used to detect both EBV VCA IgG and EBV VCA IgM. Based 
on the analysis, 96.6% of OSCC patients and 97.2% of 
control were seen positive for EBV VCA IgG, whereas 
EBV VCA IgM was not detected in both OSCC patients and 
control (Table 2). 
 EBV was reported as the most common and widespread 
human virus with lifelong latent infection (Evans 2013). 
Most of the normal adults carry EBV throughout their life 
with no ill effects and these patients usually showed an 
elevated EBV VCA IgG (Odumad et al. 2011; Riordan et 
al. 1996). Studies have shown that EBV is able to form a 
latent infection, of which it remains dormant with low viral 
expression and minimal cytopathic effects for infection 
(Sand & Jalouli 2014). Furthermore, since it takes years 
for cancer to develop, long persistence of EBV infection 
may likely to contribute to the occurrence of cancer (Farrell 
2019). Therefore, our results further support previous 
studies on the association between EBV and OSCC. 
TABLE 1. Socio-demographic profile of OSCC patients and control
OSCC samples
(n=206)
Control samples
(n=134)
No. of patients % No. of patients %
Gender
  Male
  Female
68
138
33.0
67.0
83
51
61.9
38.1
Ethnicity
  Malay
  Chinese
  Indian
  Others
47
35
102
22
22.8
17.0
49.5
10.7
91
30
12
1
67.9
22.4
9.0
0.7
Age 
(mean ± SD) 206 58.8± 14.2 134 33.5± 8.6
1972 
 On the contrary, none of the OSCC and control was 
found to be positive for EBV VCA IgM. These results 
demonstrate that both OSCC patient and control exhibit 
past EBV infection in early life and therefore seropositivity 
was only observed in EBV VCA IgG antibodies and not in 
EBV VCA IgM. The association between viral IgM and 
OSCC was not well-defined due to the fact that the onset of 
carcinogenesis by viral infection is influenced by the past 
infection or the latency of a virus (de Oliveira et al. 2016; 
Sand & Jalouli 2014).
RISK INDICATOR OF OSCC
To assess whether a certain variable could significantly 
predict the risk of OSCC, a logistic regression analysis 
was used. Based on these analyses, independent variables 
such as gender (female), and race (Indian) and age were 
identified as a significant contributor in predicting the risk 
of OCSS (Table 3). However, EBV was not found significant 
compared with the other variables further suggesting that 
past EBV infection may not play a significant role as a risk 
indicator for OSCC. 
CONCLUSION
The association of EBV with the development of OSCC 
has been extensively studied in the past. Even though this 
association has been widely reported previously (Sand et 
al. 2014), no safe conclusion was drawn from this (Sand 
& Jalouli 2014). Similarly, based on our current EBV IgG 
and IgM results, seropositivity was found in both OSCC 
and control sample. Therefore, the association between 
EBV and OSCC was not well demonstrated in this study, 
further suggesting that past EBV infection does not play a 
significant role as a risk indicator for OSCC.
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